This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk02: There will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you. Now, I would like to turn the call over to Thomas Wilson, VP of Investor Relations.
spk06: Good afternoon, everyone. Thank you for joining Thorne Health Tech's second quarter 2023 earnings call. With me today are Paul Jacobson, our CEO, Saloni Varma, our CFO, and Tom McKenna, our COO. Before we begin, please note that today's discussion contains forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those indicated by our forward-looking statements. More information about potential risk factors can be found in our 2022 Annual Report on Form 10-K and First Quarter 2023 Form 10-Q, as well as our upcoming Form 10-Q, which we anticipate filing in the next couple of days, as well as other SEC filings. Today, in addition to U.S. GAAP reporting, we will be discussing financial measures that do not conform to GAAP. We believe these non-GAAP measures enhance the understanding of our performance because they are more representative how we internally measure the business. Non-GAAP financial measures should not be considered in isolation from or as a substitute for GAAP measures. A reconciliation of GAAP to non-GAAP results is available in the earnings press release we issued after market close and in the supplemental investor presentation posted to our IR website. With that, I'll turn the call over to Paul.
spk07: Good afternoon. Thanks everyone for joining the call. Today, I'll briefly touch on our second quarter financial results and operating performance. I'll discuss our key accomplishments during the quarter. I'll provide updates for a few select products, and then I will turn to our updated 2023 guidance. Finally, Saloni will provide a detailed review of our second quarter 2023 financials, and we'll open up the call for questions after that. After posting a very strong first quarter, I'm pleased to report that our business momentum continued into the second quarter. We reported record sales of 72.7 million in Q2 on solid growth across all our sales channels, which represents year-over-year growth of 33.1%. Our direct-to-consumer business generated sales of 36.8 million, an increase of 39.3% over the second quarter of 2022. Our professional and business-to-business revenues came in at $35.9 million and grew 27.3% year-over-year. On balance, our total portfolio continues to grow across our diversified customer base, which underscores the strength of our science-backed product offerings and trust in our high-quality brand. The strong top-line performance was driven mainly by our direct-to-consumer or D2C business, which continues to perform well and exceed our internal expectations. Over the last several quarters, the strength of Thorne's D2C portfolio has enabled us to increasingly shift into a more predictable sales model. We continue to acquire new customers efficiently with an LTV to CAC ratio of 4.0, and our net promoter score of 68 remains well above industry norms. Through this success, we've experienced strong growth in subscription volumes. Thorne.com subscriptions are up approximately 60% on a year-over-year basis from strength in both daily foundation products, as well as more unique and targeted products for sports performance and metabolic health. We also continue to see healthy retention rates, which is not surprising, as the more often a customer uses our wellness products, the more likely they are to remain with us. I'm also pleased to note that we are starting to see growth in our AsiaPak business. While AsiaPak remains a nascent part of our overall sales mix, There is no question that this region is poised to become an increasingly important component of our growth and will be making appropriate investments where necessary to capitalize on this long-term opportunity. These dynamics underlie our strong top-line performance as we generate a sustainable and more predictable income stream from our growing loyal customer base around the globe. In addition to strong sales growth, we also saw a nice improvement in our margins. Second quarter gross margin of 55.9% represents a more than 100 basis point improvement over Q2 of last year. That expansion was driven by one-time benefits of lower overhead and some better channel mix favoring our direct-to-consumer business, leading to favorable impacts from pricing. We have made it a strategic priority at Thorne to invest in technology and manufacturing that should enable us to realize improved gross margins over time, and we've explained 2023 is a big investment year. As mentioned on prior calls, we expect our new manufacturing facility to be partially operational in the fourth quarter of this year and fully operational sometime during the first quarter of next year. Following completion of the build, we think this new facility will enable us to improve gross margins by another 500 to 600 basis points over the next several years, which would have a significantly positive impact to our overall profitability. resulting in a longer-term gross margin target of approximately 60% for the overall business. Turning to operating profit for the second quarter, we reported adjusted EBITDA of $12.5 million, a significant increase over the prior year period loss of $1.3 million, which was driven mainly by improved gross margin, efficient marketing spend, and operating leverage. Adjusted diluted EPS for Q2 was $0.15 versus a loss of $0.05 per share in the second quarter of last year. Now I'd like to highlight some of our second quarter accomplishments. In June, we announced that our NanoDrop device received the CE mark certification after successfully fulfilling the European Union's relevant performance, safety, and product requirements. NanoDrop, which is already integrated into Thorne's OneDraw blood collection system, is a virtually painless blood collection device that we believe has the potential to significantly decentralize clinical trials and at-home diagnostic testing. NanoDrop is a clinical grade device that uses Thorne's novel Duo Nano lancet technology to obtain capillary whole blood samples. We believe NanoDrop CE mark certification will open up new testing applications for Thorne by allowing individuals to use the device in their home. Also in June, our 510K application for NanoDrop was successfully accepted by the FDA. Soon thereafter, with no comments, we received notice from the agency that it was recommended for substantive review. Our interactions so far have been encouraging, and we expect to have a completed review by August 11th. Although even if clearance is granted, we will not be allowed to publicly announce anything until it goes live on the FDA website. This news, together with the clearance of OneDraw in Japan earlier this year, brings us one step closer to being able to achieve broad application across end markets around the globe. As a reminder, OneDraw is an FDA-cleared, small, lightweight, single-use device that attaches to the upper arm with hydrogel adhesive and vacuum. By pressing two buttons on the device, a virtually painless capillary blood sample is collected on a cartridge within OneDraw's blood collection device, which uses advanced technology to preserve the sample without requiring cold chain processing and storage. The stable, dried blood sample within the cartridge is then mailed to an independent third-party CLIA and CAHPS-certified lab for analysis, and the results, insights, and recommendations can be viewed on our health intelligence platform by the individual and their healthcare practitioner. OneDraw enables better health for individual consumers and patients by removing the obstacles that prevent people from taking better control of their health, ultimately offering an improved experience. We are obviously very excited about OneDraw technology and believe this highly innovative product has the opportunity to bring significant upside to our future sales growth. And we are not alone in this assessment of OneDraw's technology. In May, we announced that OneDraw won the prestigious 2023 MedTech Breakthrough Award for Best Overall Medical Device. With competition from nearly 4,000 other product nominations globally, we couldn't be more pleased to be recognized among such a large number of cutting-edge technologies and new innovations. Also in May, we announced a research and development partnership agreement with Aromi Science, a leader in metabolomics, to develop a next-generation metabolomics wellness test We have seen nice sales growth in metabolism-related offerings and believe that metabolomics is fast becoming one of the most valuable measurements to assess the overall health status of an individual on a real-time basis. Initially, we plan on conducting a series of validation studies and will collect additional data using our OneDraw device. If successful, this research will be used to support the development of metabolomics commercial tests that can be offered across our entire customer base. In early April, we announced significant positive findings from a randomized double-blind trial that studied the effects of the dietary supplement Synequel on brain function and structure in junior-A ice hockey players. Synequel is a nutrient blend that has been co-developed with neurologists at the Mayo Clinic for supporting brain health structure and function, especially for athletes and other individuals engaged in high-contact activities. The study results provided clear clinical evidence that our patented, multi-ingredient nutritional supplement Synequel can support healthy brain structure and cognitive function. Developing products that support brain health remains a core focus at Thorne, and we continue to work collaboratively with the Mayo Clinic and Health Tech Connects to further advance Synequel's development. We expect to devote significant marketing efforts to this product beginning in 2024. On July 25th, we kicked off our Build to Last marketing campaign, which is our first-ever global campaign and features three-time NBA champion, philanthropist, and entrepreneur Dwayne Wade, along with his son and professional basketball player Zaire Wade. The three-month campaign showcases an inspirational, no-shortcuts approach to lifelong wellness, supported by Thorne's highly tested premium products that are capable of enriching lives at every age and life stage. With our efficient marketing engine, we expect the campaign and our partnership with the Wade family to scale our brand and product awareness in major markets across the globe. Turning to our outlook, we expect continued momentum across our business as we enter the second half of the year. This momentum is driven by the launch of additional innovative products, an expansion to our sales force that is producing more business wins, a growing international presence, and increasing brand awareness of the Thorne name. Based on the strength of our first half results, we are raising the low ends of our full year 2023 guidance ranges for both net sales and gross margin. With these increases to the guidance midpoints, our updated full year guidance range for net sales is $285 to $290 million, and our updated full year guidance range for gross margin is between 50 and 52%. We are also increasing the midpoint of our guidance for marketing costs, raising the prior range of between 13% and 15% of net sales to a range of between 14% and 15% of net sales. The increase is consistent with our prior commentary, which indicated that marketing costs may approach the high end of the range due to increased investment this year, including from anticipated spend for the Build to Last marketing campaign. Rounding out our guidance with increased marketing spend, natural growth in selling and distribution costs to meet demand, as well as hiring into our plant expansion, we are maintaining our guidance for full-year adjusted EBITDA of between $30 and $32 million. However, we are raising our full-year adjusted diluted EPS of $0.26 to $0.32 per share from an update to our estimated and annual tax rate in Q2, which Saloni will cover in more detail. We remain confident that based on our continued strength in our business, we can achieve this updated guidance. With that, I'll turn the call over to Solani for her prepared remarks on her financial results and capital deployment priorities for the rest of the year.
spk03: Thank you, Paul. Good afternoon, everyone. Today, I'll walk you through our results for the second quarter, provide details on our planned expansion and related financing activities, and share some additional commentary on our expectations for the remainder of the year. Our second quarter results exceeded our internal expectations. On the top line, Q2 net sales of 72.7 million represent our highest quarterly sales and record, resulting in growth of 33.1% year-over-year. We continue to see strength in our D2C business, which represented over 50% of net sales for the second consecutive quarter. D2C growth was primarily driven by favorable pricing increases, product rationalizations, and our ever-expanding customer base. With this trend of our generally higher-end consumer continuing to hold thus far, it's clear that while there has been pullback in spending on discretionary items at the macro level, spending on products that people depend on for their health and wellness goals has stayed more insulated. Our strong sales performance continues to be underpinned by healthy growth in unique new customers, which increased approximately 86% over Q2 of last year, with the number of active subscriptions up over 60%. Those increases helped to drive 39.3% sales growth in our B2C channel, which was also up 8.8% on a sequential quarter basis. Professional and B2B channel sales were up 27.3% year over year. Our ability to use digital marketing and build out on the direct sales force of a traditionally small base have helped deliver growth across the customer groups captured in the professional and B2B channel. More importantly, our acquisition of new customers continues to be extremely efficient with a healthy LTV to cap ratio of four for the second quarter. Our net promoter score of 68 went back up closer to historical norms, mainly from having worked through backorder positions for certain products. Once our new World Health Production Facility is fully operational in Q1 2024, the capacity constraints we experienced from time to time are not expected to be an ongoing hurdle. Our second quarter growth margin of 55.9% increased by more than 100 basis points year-over-year. As Paul mentioned, that was largely a function of one-time benefits from lower overheads, favorable channel mix, as our high growth margin channels continue to deliver significant growth, along with the impact of our price increases taken earlier this year. Some of these benefits were offset with higher raw material costs as we sell through the last of our higher-priced raw materials from 2022. Looking ahead, in H2, we expect some margin compression from incremental labor and overheads as we walk through capacity constraints that will require temporary use of command to help keep pace with demand while we complete the expansion over the next few quarters. Turning to operating expenses, R&D costs decreased 13.6% to 1.5 million, representing 2.1% of net sales. That decrease was driven by incurring higher costs in the second quarter of 2022, associated with one draw ahead of our FDA submission, as well as finalizing the relaunch of our gut health test with its first-in-market wipe technology. While we did not have the same magnitude of R&D activities in Q2 2023, our core R&D engine remains efficient and flexible as demonstrated by a continued high volume of ongoing clinical studies and product launches born out of AI-driven insights from our expanding pool of clinical data. Our marketing spend for the second quarter was $10 million down 36.6% and representing 13.8% of Q2 net sales. We have optimized our marketing spend as we continuously evaluate the benefits of our spend on our various businesses. As stated on prior calls, while we intend to deploy marketing dollars more evenly than in the past, We will continue to hold large marketing campaigns like our new team-launched Build to Love campaign during the rain, rain, rain, and zire, zire, zire, zire, zire, zire, zire, zire, zire, zire, zire, zire, zire, zire. With the campaign, we are deploying marketing and technology in a great way, with an intensive focus on the production of health and health care levels. In addition, we move to more facilities on brand-to-brand. We believe that more personalized digital technology and high-impact resources will benefit our retention, higher engagement with customers, elevate the brand, and drive customer optimization and scale. Second quarter S&A expense of 22.5 million, that's 21.4% year-over-year, and rest of the 30.9% sales. A decrease of 3.8 million points year-over-year. Most of the four billion dollar increase over Q2 of last year was from a higher selling cost, including our growing sales force, increased rent housing, inflation and expenses, and our commission sentence. On balance, our daily costs on rent homes have continued to be increased in extension, and we are getting leveraged benefits from economic scale, where and when possible. Turning to the value of money, specifically our structure of liquidity, we ended up with over $157.1 billion. We have another $15.1 billion of specific cash, better value, and we destroyed a lot of the long extension. As a result, our total cash distribution of $2.3 million as of June 2018 was slightly above our total outstanding borrowing of $27.9 million, including over $1 million of obligations. The plan can translate into a total loss of RMR for a total utility fee of $0, before it participates in steady recovery in the next year. As of 2018, we had more than $50.1 billion in development capacity on our wall wall wall, with an option to expand that to an additional $10 million. As a reminder, we broke ground on the expansion of our manufacturing facility in South Carolina in the quarter of 2022, after 500 traffic flows following the relocation of our operation in South Carolina in 2018. We agree that construction should be largely completed by the end of this year, and that the extended area of facilities will be fully operational by the end of Q1 2024. Upon completion, our workforce facilities will be ramped and stockpiled globally among such and such and such and such, and such and such, and such and such. By doubling the size of all the sales, we will be able to economically scale at far superior levels while expanding our production capabilities and largely pay in support of our R&D operation and product development. In addition to the financial expansion, we completed the financial expansion of our new warehousing and facility, which is now fully operational. That expansion will lead to our current operations in South Carolina and will drive long-term interlibrary efficiency in our production, warehousing, and fulfillment. The total cost of our interlibrary expansion is estimated to be approximately $16,000. We continue to make excellent progress on our interlibrary efficiency by providing purchase machinery for double-dub production, expanding the design by an additional 7,000 square feet. We are funding all our traffic needs will make the internal cash from operations, it will finance financing, the wall will fall over, and it's going to be made with allowance by the existing landlord. Of the total traffic of $15 million, $14 million has been incurred until the end of June 2023. We anticipate funding nearly $20 million with $13 million of restricted cash value sheets and $8 million of 10-inch rolling allowance. With no other significant cap-to-cap projects in the pipeline, upon completing the construction, we expect to reward the negative cash capital that has been needed in the project. With the cost we have earned today and our remaining capital expense, our full-year capital guidance, approximately $5 to $38 million, is supplemental to our updated 2023 full-year guidance that calls for net sales between $285 to $290 million, up from the prior guidance range of $280 million to $290 million. Gross margins of between 50% to 52%, up from the prior guidance range of 49 to 52%. Adjusted EBITDA of 30 to 32 million, which remains unchanged. An adjusted EPS of 26 cents to 32 cents, a slight increase to the low and high ends of the range, solely from updating our tax rates during Q2. In addition to the above data guidance, we are also updating our guidance for marketing spend to a range between 14 to 15% of net sales, up from our prior range of 13 to 15% of net sales. We are reaffirming other prior guidance measures for 2023, including depreciation and amortization of approximately 2.5% of sales, gradually increasing as new assets come online over the course of the year. Interest expense of approximately 1% of sales, and diluted weighted average shares outstanding of $54 million. As mentioned, during the second quarter, we updated our estimated full-year tax rate based on applicable jurisdictional rates, which reduced our full-year expected tax rate from 26% to 22.9%, which results in a mathematical lift to EPS from applications at lower rate. In summary, we expect our pace of innovation and investment in our product portfolio will continue to drive growth and lasting value across our end markets. We are pleased with our Q2 results across the board, which were in line with our internal expectations. We are still expecting a sales ramp in the second half of the year. We also still expect that our margins and free cash flow will be compressed relative to historical norms during a plant expansion before gradually increasing once expansion is complete. I look forward to updating you on our progress.
spk01: With that, I'll open the lines for your questions. Operator?
spk02: At this time, I would like to remind everyone that in order to ask a question, press star, then the number one on your telephone keypad. We will pause for just a moment to compile the Q&A roster. All right, your first question comes from Susan Anderson, Canaccord Genuity. Susan, please go ahead.
spk04: Hi, good evening. Nice job on the quarter. I was wondering if you could talk about the, I think it was 400 or 500 basis points of margin, gross margin expansion longer term, which would get you to that high 50% range. I guess, I don't know if you could bucket maybe just kind of the drivers to get you there.
spk01: Hi, Susan. Good afternoon. This is Saloni.
spk03: Hi. So happy to walk through that. A lot of it is coming from efficiency gains. As we anticipate growing, we are going to double our production capacity. We will go up to $750 million in revenue. So what has happened is this year, because of some capacity constraints, we have had to do co-manufacturing. And going forward, we expect the benefit of that. That will help us significantly, and it will be an immediate benefit in the next two years. Beyond that, it would be labor and overheads. So our lease accounting, the new standards that are in place, make us amortize rent evenly over the course of the time period of the lease. However, as we ramp up capacity, the absorption of that works differently and our cost of production will come down significantly. And then from a capacity perspective, our labor cost, while we will be looking to ramp it up slowly, however, full utilization by year four will lead to much better overhead absorption. There is some level of product mix in this, but majority of this would come through efficiencies in volume, scale, and some level of product mix benefits.
spk04: Okay, Glenn.
spk07: You're referring to the margin in this quarter, right? Not the long, or the long term?
spk04: No, longer term. Yeah, I know. Okay, fine. Yeah, correct. Yeah. Good. Yeah, that was really helpful. And then if I could just add one more, I think the growth in subscriptions, it looks like it did accelerate a bit, about 60% now. Maybe if you could just talk about what you think the drivers were in that acceleration?
spk05: Yeah, I think, again, it just is – go ahead. All right.
spk03: No, I think, Susan, what we have done this year is we have consistently invested in the brand and communicating the benefits behind the science and the quality of our products. Last year in H2, we were not looking to spend as much. And this year, one of the big reasons is we have increased our marketing forecast for this year. Originally, it was around 13% to 15%. Now we're looking at 14% to 15%. because we do want to invest in consumer education. So one of the biggest drivers is the consistent investment across all channels. It's not just on Pond.com, but even on Amazon, and targeting digital marketing for our HCP professionals has definitely helped communicate the message across all channels.
spk04: Great. That's really great. Thanks so much, you guys. Good luck the rest of the year. Thank you.
spk02: Reminder to ask a question, press star, then the number one on your telephone keypad. Your next question comes from Elizabeth Anderson, Evercore. Elizabeth, please go ahead.
spk00: Hi, this is Patrick on for Elizabeth. Congrats on the quarter, guys. Are there any changes or new macro developments we should be considering for the remainder of the year besides those mentioned, whether it be Russia, Ukraine, those impacts extending, or anything else high level? Thanks.
spk07: No, I don't think so. You know, everything for us right now is more on a micro basis. So we're focused on a lot of new product launches, both device and product. that will be coming out later on this year, but we're not particularly concerned about the macro stuff right now.
spk05: We've already taken the hit, and don't see the Russia-Ukraine situation turning around positively. Got it. Thank you.
spk01: Ladies and gentlemen, that concludes today's call. Thank you all for joining and you may now disconnect. That concludes today's call. Thank you all for joining and you may now disconnect.
Disclaimer